Healthcare provider profile · identity verified

Monica Janssen

Nurse Practitioner · CASPER, WY · NPI 1356712293

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	358	70
Lisinopril	Lisinopril	310	68
Atorvastatin Calcium	Atorvastatin Calcium	236	63
Amlodipine Besylate	Amlodipine Besylate	172	41
Pantoprazole Sodium	Pantoprazole Sodium	168	39
Omeprazole	Omeprazole	141	34
Metformin Hcl	Metformin Hcl	133	35
Gabapentin	Gabapentin	132	31
Rosuvastatin Calcium	Rosuvastatin Calcium	130	37
Montelukast Sodium	Montelukast Sodium	120	28
Escitalopram Oxalate	Escitalopram Oxalate	107	18
Losartan Potassium	Losartan Potassium	106	31
Ozempic	Semaglutide	98	15
Albuterol Sulfate Hfa	Albuterol Sulfate	97	33
Tamsulosin Hcl	Tamsulosin Hcl	94	21
Sertraline Hcl	Sertraline Hcl	88	17
Trazodone Hcl	Trazodone Hcl	85	17
Metoprolol Succinate	Metoprolol Succinate	83	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	80	18
Furosemide	Furosemide	80	27
Simvastatin	Simvastatin	79	20
Metformin Hcl Er	Metformin Hcl	75	15
Clopidogrel	Clopidogrel Bisulfate	74	16
Potassium Chloride	Potassium Chloride	73	24
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	61	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	61	14
Hydrochlorothiazide	Hydrochlorothiazide	60	16
Hydroxyzine Hcl	Hydroxyzine Hcl	59	suppressed
Tramadol Hcl	Tramadol Hcl	59	14
Quetiapine Fumarate	Quetiapine Fumarate	57	suppressed
Duloxetine Hcl	Duloxetine Hcl	56	13
Eliquis	Apixaban	55	13
Metoprolol Tartrate	Metoprolol Tartrate	50	suppressed
Pregabalin	Pregabalin	48	11
Allopurinol	Allopurinol	45	12
Carvedilol	Carvedilol	45	suppressed
Buspirone Hcl	Buspirone Hcl	44	11
Warfarin Sodium	Warfarin Sodium	44	12
Fluticasone Propionate	Fluticasone Propionate	43	15
Pravastatin Sodium	Pravastatin Sodium	42	suppressed
Spironolactone	Spironolactone	41	suppressed
Mounjaro	Tirzepatide	40	suppressed
Torsemide	Torsemide	38	11
Venlafaxine Hcl Er	Venlafaxine Hcl	38	suppressed
Mirtazapine	Mirtazapine	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	36	suppressed
Glipizide	Glipizide	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Lorazepam	Lorazepam	34	suppressed
Memantine Hcl	Memantine Hcl	34	suppressed
Trulicity	Dulaglutide	34	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	33	16
Farxiga	Dapagliflozin Propanediol	33	suppressed
Chlorthalidone	Chlorthalidone	32	suppressed
Famotidine	Famotidine	32	suppressed
Breo Ellipta	Fluticasone/Vilanterol	30	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Alprazolam	Alprazolam	28	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Glipizide Er	Glipizide	28	suppressed
Hydrocortisone	Hydrocortisone	28	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Vilazodone Hcl	Vilazodone Hcl	26	suppressed
Estradiol	Estradiol	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Nystatin	Nystatin	24	12
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Repatha Syringe	Evolocumab	24	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	16
Atenolol	Atenolol	21	suppressed
Finasteride	Finasteride	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	20	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	20	suppressed
Prednisone	Prednisone	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Lansoprazole	Lansoprazole	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Spiriva Handihaler	Tiotropium Bromide	17	suppressed
Baclofen	Baclofen	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Colchicine	Colchicine	15	suppressed
Dexlansoprazole Dr	Dexlansoprazole	15	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Prazosin Hcl	Prazosin Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Anastrozole	Anastrozole	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Temazepam	Temazepam	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Jantoven	Warfarin Sodium	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed
Scopolamine	Scopolamine	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Trimethoprim	Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error